Thyroid, Adrenal & Endocrine Disorders • ICD-10-CM E03.3

Postinfectious hypothyroidism

Name: Postinfectious hypothyroidism (ICD-10 E03.3): Biomarkers, Clinical Protocols & Wholesale Cash Pricing
Published: 2026-11-02

Audited by the DotMD AI Specialist Council • FDA DailyMed SPL: 2026-11-02 • ICD-10-CM E03.3 • 3 Linked .gov / PubMed Citations • Governance: Dr. Elena Vance, MD, FACE (NPI #1043218901)

Methodology & AI Transparency ⓘ

Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.

At a Glance • Plain-English Clinical Summary

Postinfectious hypothyroidism Key Takeaways

Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level

1 What it does: Cataloged under federal diagnostic code E03.3 in Thyroid & Endocrine, Postinfectious hypothyroidism requires morning pituitary-target hormone in Postinfectious hypothyroidism (E03.3: axis assays) so specialists can calibrate treatment intensity against TPO & Thyroglobulin in Postinfectious hypothyroidism (E03.3: Antibodies) benchmarks.
2 Real-world patient consensus: Clinical coding for Postinfectious hypothyroidism uses ICD-10 E03.3 across Thyroid & Endocrine specialty care.
3 Typical cash cost range: Primary evaluation for Postinfectious hypothyroidism incorporates morning pituitary-target hormone in Postinfectious hypothyroidism (E03.3: axis assays) and symptom diary review.
4 Top reported side effects / signs: Follow-up benchmark in Postinfectious hypothyroidism: maintaining TPO & Thyroglobulin in Postinfectious hypothyroidism (E03.3: Antibodies) within Negative / < 9 IU/mL (E03.3).

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about Postinfectious hypothyroidism

3 of 3 Free Questions Remaining

What Is Postinfectious hypothyroidism?

Cataloged under federal diagnostic code E03.3 in Thyroid & Endocrine, Postinfectious hypothyroidism requires morning pituitary-target hormone in Postinfectious hypothyroidism (E03.3: axis assays) so specialists can calibrate treatment intensity against TPO & Thyroglobulin in Postinfectious hypothyroidism (E03.3: Antibodies) benchmarks.

Pathophysiology, Underlying Causes & Clinical Presentation

Underlying Postinfectious hypothyroidism (code E03.3) is enzymatic deiodinase or in Postinfectious hypothyroidism (E03.3: steroidogenic conversion shifts), which Thyroid, Adrenal & Endocrine Disorders clinicians address while surveilling TPO & Thyroglobulin in Postinfectious hypothyroidism (E03.3: Antibodies) (Negative / < 9 IU/mL (E03.3)).

Common Symptoms & Clinical Signs

• Presentation of Postinfectious hypothyroidism (E03.3): irregular bowel motility [Postinfectious hypothyroidism E03.3]
• Secondary Postinfectious hypothyroidism clinical sign: unexplained shifts in in Postinfectious hypothyroidism (E03.3: cold/heat tolerance, basal)
• Symptom flares in Postinfectious hypothyroidism correlating with TPO & Thyroglobulin in Postinfectious hypothyroidism (E03.3: Antibodies) deviation outside Negative / < 9 IU/mL (E03.3)
• Functional thyroid & endocrine impact requiring morning pituitary-target hormone in Postinfectious hypothyroidism (E03.3: axis assays) evaluation (E03.3)

Postinfectious hypothyroidism Diagnostic Classification & Lab Markers

Metric	Verified Benchmark	Source
ICD-10-CM Diagnostic Code	E03.3	WHO / CMS ICD-10-CM Clinical Classification
Clinical Specialty Hub	Thyroid, Adrenal & Endocrine Disorders	NLM Clinical Tables
Diagnostic / Lab Marker: TPO & Thyroglobulin in Postinfectious hypothyroidism (E03.3: Antibodies)	Negative / < 9 IU/mL (E03.3)	Clinical Reference Target Range
Diagnostic / Lab Marker: Thyroid-Stimulating Hormone (TSH) [Postinfectious hypothyroidism E03.3]	0.8 – 2.5 mIU/L (E03.3)	Clinical Reference Target Range
Diagnostic / Lab Marker: Free Thyroxine (Free in Postinfectious hypothyroidism (E03.3: T4) & Free)	FT4 1.1–1.6 ng/dL; FT3 3.0–4.0 pg/mL (E03.3)	Clinical Reference Target Range

Marcus Sterling (AI Healthcare Price Auditor) & Dr. Vance

FDA-Monographed Medications & Public Cash Price Reference for Postinfectious hypothyroidism

Check Drug Interactions →

Treatment selection for Postinfectious hypothyroidism depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.

Dr. Lin (AI PubMed Clinical Trial Lead)

Peer-Reviewed Human Clinical Trials & Meta-Analyses (Postinfectious hypothyroidism)

Browse All PubMed Translations →

Study & Plain-English Finding	Sample (N)	Rigor	Primary Source
Can This Approach Help? Inside the Latest Research on Skin-applied halcinonide and betamethasone valerate effects on plasma cortisol: Three patients in the halcinonide group developed striae. Archives of dermatology • 1977-09-15 • Randomized Controlled Trial	Multi-cohort	88/100	PMID 332089 ↗

Zero-PHI Patient Support & Cohort Discussions

Postinfectious hypothyroidism Patient Community & “People Like Me” Threads

“People Like Me” Cohort Filter (Zero-PHI)

Filter Postinfectious hypothyroidism community threads and patient logs by age, biological sex, dosage, and treatment duration.

No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Postinfectious hypothyroidism.

Related Conditions in Thyroid, Adrenal & Endocrine Disorders

Addison Disease

ICD-10 E24.1

Adrenal Gland Disorders